Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
Sign Up to like & getrecommendations! Published in 2024 at "Hepatology"
DOI: 10.1097/hep.0000000000001163
Abstract: Background and Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)–based systemic therapies is unclear. Approach and Results: Retrospective study of patients with HCC who had CR according… read more here.
Keywords: therapy; ici based; achieved complete; complete response ... See more keywords
Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.8_suppl.66
Abstract: 66 Background: Patients with mRCC with S/R components tend to have a poor prognosis with few therapeutic options available. Recent data suggest that immune checkpoint inhibitor (ICI)-based therapies may be especially effective for these patients.… read more here.
Keywords: patients mrcc; based therapies; first line; ici based ... See more keywords
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.584
Abstract: 584 Background: I-SPY2 was the first randomized trial to demonstrate an improvement in pCR and EFS when Immune Checkpoint Inhibitors (ICI) were added to standard neoadjuvant chemotherapy. This finding was validated in the phase 3… read more here.
Keywords: ici based; trial; adrenal insufficiency; incidence ... See more keywords
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-22-376
Abstract: Background Although immune checkpoint inhibitors (ICIs) provide unprecedented survival improvement for patients with advanced non-small cell lung cancer (NSCLC), disease progression inevitably occurs. After ICIs failure, limited data exist on whether ICI-based treatment beyond progression… read more here.
Keywords: progression; based treatment; ici based; prior immunotherapy ... See more keywords
Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Current Evidence and Future Directions
Sign Up to like & getrecommendations! Published in 2025 at "Oncology Research"
DOI: 10.32604/or.2025.065818
Abstract: Cancer immunotherapy has long been established as an important treatment option for cancers. In particular, Immune Checkpoint Inhibitor (ICI) has been reported to be effective against various gastrointestinal cancers (esophageal cancer, gastric cancer, colorectal cancer);… read more here.
Keywords: cancer; treatment; immune checkpoint; ici based ... See more keywords
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1161718
Abstract: Introduction Platinum-based chemotherapy is still the standard of care for Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients after developing EGFR-TKI resistance. However, no study focusing on the role of immuno… read more here.
Keywords: based treatment; nsclc patients; egfr tki; ici based ... See more keywords
Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.920047
Abstract: Purpose To evaluate the outcomes of immune checkpoint inhibitor (ICI)-based treatments versus classical chemotherapy for metastatic non-small cell lung cancer (NSCLC) patients who develop epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance and to… read more here.
Keywords: based therapy; egfr tki; tki resistance; ici based ... See more keywords
How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15041324
Abstract: Simple Summary Unresectable hepatocellular carcinoma (HCC) is the main type of primary liver cancer and poses a challenge to the healthcare system across the world. Immune checkpoint inhibitor (ICI)-based immunotherapy has become a recent focus… read more here.
Keywords: hepatocellular carcinoma; hcc; locoregional interventional; ici based ... See more keywords